Welcome to our dedicated page for Accendra Health SEC filings (Ticker: ACH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Accendra Health, Inc. filings document operating results, material events and capital-structure matters for a NYSE-listed home healthcare company with common stock trading under ACH. Form 8-K reports furnish quarterly and annual financial results and record material agreements, shareholder voting matters and balance-sheet disclosures.
Proxy materials describe governance, executive compensation and related shareholder matters. The filings also identify the company as a Virginia corporation and provide formal disclosure around its continuing operations following the completed sale of its former Products & Healthcare Services business.
Accendra Health President & CEO Edward A. Pesicka reported a tax-related share disposition, not an open-market stock sale. On the Form 4, 58,945 shares of common stock were surrendered at $2.03 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold to outside investors. After this transaction, Pesicka directly holds 1,090,477 shares of Accendra Health common stock, indicating he retains a substantial equity position in the company.
ACCENDRA HEALTH INC/VA/ executive reports routine tax withholding share disposition. EVP & CFO Jonathan A. Leon surrendered 11,286 shares of common stock on 2026-03-20 to the company to cover tax withholding tied to vesting of restricted stock. This was not an open-market sale. After the transaction, he directly holds 292,303 shares of common stock.
Accendra Health executive Perry A. Bernocchi reported a routine tax-related share disposition. On March 20, 2026, he surrendered 20,841 shares of common stock at $2.03 per share to the company to satisfy tax withholding obligations tied to vesting restricted stock. This was not an open-market sale, and he still directly holds 321,821 shares after the transaction.
Accendra Health executive Heath H. Galloway transferred 9,347 shares of common stock to the company at $2.03 per share to cover tax withholding on vested restricted stock. This non‑market, tax-withholding disposition leaves him holding 169,094 shares directly, reflecting a routine compensation-related adjustment rather than an open-market trade.
Bernocchi Perry A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health executive Perry A. Bernocchi, EVP and Chief Operating Officer, received a grant of 108,696 shares of Common Stock as equity compensation. The restricted stock grant vests one-third per year over three years. Following this award, his directly held stake totals 342,662 shares.
Leon Jonathan A reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ EVP & CFO Jonathan A. Leon received a grant of 85,067 shares of common stock. The shares are restricted stock that vest one-third per year over three years, meaning they become fully owned gradually over time. After this award, he directly holds 303,589 common shares. This is a compensation-related equity grant at no cash cost and does not involve any open-market buying or selling.
Galloway Heath H reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ granted EVP, General Counsel & Corporate Secretary Heath H. Galloway 61,437 shares of Common Stock as a restricted stock award. The grant carries no purchase price and vests one-third per year over three years. Following this compensation award, Galloway directly holds 178,441 Common Stock shares. This is a non-market, equity-based compensation grant rather than an open-market purchase or sale, so it reflects long-term incentive alignment more than a trading view on the stock.
Accendra Health, Inc. outlines a major reshaping of its business and key risks. The company completed the sale of its Products & Healthcare Services business for $375 million in cash, retaining a 5% equity interest, which leaves it as a smaller, single-segment home healthcare provider.
Management highlights heavy reliance on a few commercial and government payors. One large commercial payor is terminating contracts that represented $322 million, or 12% of 2025 net revenue, including nearly all capitation revenue, creating meaningful earnings and liquidity risk if not replaced or offset.
The filing stresses competitive pressures, supplier concentration, cybersecurity threats, inflation, and reimbursement uncertainty from Medicare, Medicaid and private payors. It also discusses extensive regulatory exposure, including privacy, fraud and abuse, environmental and antitrust rules, and notes Apria’s prior False Claims Act settlement and ongoing Corporate Integrity Agreement obligations through 2026.
Accendra Health, Inc. reported fourth-quarter and full-year 2025 results that reflect its shift to a standalone home-based care business after completing the sale of its Products & Healthcare Services business on December 31, 2025.
From continuing operations, net revenue rose to $708.967 million in Q4 2025 from $695.023 million a year earlier, with Q4 operating income improving to $20.9 million from a loss of $272.7 million. For 2025, continuing net revenue grew to $2.762 billion from $2.680 billion, and adjusted EBITDA was $374.847 million versus $370.515 million in 2024.
Despite better underlying performance, the company recorded a substantial full-year net loss of $1.1006 billion, driven largely by a $997.960 million loss from discontinued operations and an $80 million transaction breakage fee related to a terminated acquisition. Cash and cash equivalents increased markedly to $281.989 million at December 31, 2025, and net debt declined to $1.768 billion, while total equity moved to a deficit position. Management highlighted strong cash flow, ongoing cost controls and balance sheet optimization as it completes separation from Owens & Minor and focuses on sustainable growth.
Accendra Health Inc. received a Schedule 13G from Charles Schwab Investment Management Inc. showing a significant institutional position in its common stock. Charles Schwab Investment Management reports beneficial ownership of 4,057,056 shares, representing 5.24% of the outstanding common stock as of the triggering date.
The filing states that Schwab has sole voting and sole dispositive power over all 4,057,056 shares, with no shared voting or dispositive authority. Schwab certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Accendra Health.